Thrombotic risk assessment in antiphospholipid syndrome: The role of new antibody specificities and thrombin generation assay

Clinical and Molecular Allergy

Volumn 14, Issue 1, 2016, Pages

  Sciascia, Savino ^a   Baldovino, Simone ^a   Schreiber, Karen ^b,c   Solfietti, Laura ^a   Radin, Massimo ^a   Cuadrado, Maria J ^b   Menegatti, Elisa ^a   Erkan, Doruk ^d,e   Roccatello, Dario ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c Mental Health Center Glostrup   (Denmark)

^d Barbara Volcker Center for Women and Rheumatic Diseases   (United States)

^e HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Anti prothrombin; Anti 2 glycoprotein I antibodies; Antiphospholipid antibodies; Antiphospholipid antibody; Antiphospholipid syndrome; APS action; Clinical trials; Lupus anticoagulant; Miscarriages; Pregnancy loss; Risk assessment; Thrombin generation assay; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; DOMAIN 1 BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; LIPOCORTIN 2 ANTIBODY; LIPOCORTIN 5 ANTIBODY; PHOSPHATIDYLETHANOLAMINE ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; PROTHROMBIN ANTIBODY; THROMBIN; UNCLASSIFIED DRUG; VIMENTIN ANTIBODY;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLOOD CLOTTING TEST; CLINICAL FEATURE; DEEP VEIN THROMBOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GOOD CLINICAL PRACTICE; HUMAN; LABORATORY TEST; LUNG EMBOLISM; LUPUS ANTICOAGULANT TESTING; PREGNANCY COMPLICATION; PRIMARY PREVENTION; RADIOIMMUNOASSAY; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; THROMBIN TIME; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84982293213     PISSN: None     EISSN: 14767961     Source Type: Journal    
DOI: 10.1186/s12948-016-0043-2     Document Type: Review

References (61)

1. Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64:504-12. Available from http://www.ncbi.nlm.nih.gov/pubmed/21953404.
2. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: the global anti-phospholipid syndrome score. Rheumatology. 2013;52:1397-403. Available from http://www.ncbi.nlm.nih.gov/pubmed/23315788.
3. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. The global anti-phospholipid syndrome score in primary APS. Rheumatology. 2015;54:134-8. Available from http://www.ncbi.nlm.nih.gov/pubmed/25122726.
4. Wang S, Hsieh E, Zhu L, Wu B, Lu L. Comparative assessment of different health utility measures in systemic lupus erythematosus. Sci Rep. 2015;5:13297. Available from http://www.ncbi.nlm.nih.gov/pubmed/26293686.
5. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306. Available from http://www.ncbi.nlm.nih.gov/pubmed/16420554.
6. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498-509. Available from http://www.ncbi.nlm.nih.gov/pubmed/20822807.
7. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7:330-9. Available from http://www.ncbi.nlm.nih.gov/pubmed/21556027.
8. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust NZ J Med. 1990;20:231-6. Available from http://www.ncbi.nlm.nih.gov/pubmed/2115326.
9. de Groot PG, Lutters B, Derksen RHWM, Lisman T, Meijers JCM, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005;3:1993-7. Available from http://www.ncbi.nlm.nih.gov/pubmed/16102105.
10. Jeleniewicz R, Majdan M, Targońska-Stȩpniak B, Dryglewska M. Prevalence of antiphospholipid antibodies in rheumatoid arthritis patients and relationship with disease activity. Pol Arch Med. 2012;122:480-6. Available from http://www.ncbi.nlm.nih.gov/pubmed/22910193.
11. Mok CC, Tang SSK, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum. 2005;52:2774-82. Available from http://www.ncbi.nlm.nih.gov/pubmed/16142761.
12. Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Salvatore S, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis. 2011;70:1083-6. Available from http://www.ncbi.nlm.nih.gov/pubmed/21285115.
13. Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?. Semin Thromb Hemost. 2012;38:322-7. Available from http://www.ncbi.nlm.nih.gov/pubmed/22399307.
14. Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118:4714-8. Available from http://www.ncbi.nlm.nih.gov/pubmed/21765019.
15. Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Bertolaccini ML. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost. 2012;10:2512-8. Available from http://www.ncbi.nlm.nih.gov/pubmed/23025466.
16. Sciascia S, Bertolaccini ML, Roccatello D, Khamashta MA. Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis. 2013;72:142-3. Available from http://www.ncbi.nlm.nih.gov/pubmed/22843492.
17. Sciascia S, Cosseddu D, Montaruli B, Kuzenko A, Bertero MT. Risk Scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis. 2011;70:1517-8. Available from http://www.ncbi.nlm.nih.gov/pubmed/21402561.
18. Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74:1011-8. Available from http://www.ncbi.nlm.nih.gov/pubmed/24464962.
19. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M et al. Update of the guidelines for lupus anticoagulant detection. J Thromb. Haemost. 2009;7:1737-40. Available from http://www.ncbi.nlm.nih.gov/pubmed/19624461.
20. Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R et al. 14th international congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014;13:917-30. Available from http://www.ncbi.nlm.nih.gov/pubmed/24824074.
21. Moore GW, Culhane AP, Daw CR, Noronha CP, Kumano O. Mixing test specific cut-off is more sensitive at detecting lupus anticoagulants than index of circulating anticoagulant. Thromb Res. 2016;139:98-101. Available from http://www.ncbi.nlm.nih.gov/pubmed/26916303.
22. Pengo V, Ruffatti A, Tonello M, Hoxha A, Bison E, Denas G, et al. Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles. Thromb Res. 2015;136:161-3. Available from http://www.ncbi.nlm.nih.gov/pubmed/25959581.
23. Pengo V, Ruffatti A, Tonello M, Cuffaro S, Banzato A, Bison E, et al. Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost. 2015;13:782-7. Available from http://www.ncbi.nlm.nih.gov/pubmed/25645395.
24. Meroni PL, Chighizola CB, Rovelli F, Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther. 2014;16:209. Available from http://www.ncbi.nlm.nih.gov/pubmed/25166960.
25. Meijide H, Sciascia S, Sanna G, Khamashta MA, Bertolaccini ML. The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev. 2013;12:421-5. Available from http://www.ncbi.nlm.nih.gov/pubmed/22951216.
26. Bertolaccini ML, Sciascia S, Murru V, Garcia-Fernandez C, Sanna G, Khamashta MA. Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant. Thromb Haemost. 2013;109:207-13. Available from http://www.ncbi.nlm.nih.gov/pubmed/23254928.
27. Sciascia S, Khamashta MA, Bertolaccini ML. New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies. Curr Rheumatol Rep. 2014;16:415. Available from http://www.ncbi.nlm.nih.gov/pubmed/24609824.
28. Staub HL, Bertolaccini ML, Khamashta MA. Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev. 2012;12:230-4. Available from http://www.ncbi.nlm.nih.gov/pubmed/22796282.
29. Hirmerova J, Ulcova-Gallova Z, Seidlerova J, Filipovsky J, Bibkova K, Micanova Z, et al. Laboratory evaluation of antiphospholipid antibodies in patients with venous thromboembolism. Clin Appl Thromb Hemost. 2010;16:318-25. Available from http://www.ncbi.nlm.nih.gov/pubmed/19221100.
30. Sanmarco M, Gayet S, Alessi M-C, Audrain M, de Maistre E, Gris J-C, et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost. 2007;97:949-54. Available from http://www.ncbi.nlm.nih.gov/pubmed/17549297.
31. Sanmarco M, Alessi MC, Harle JR, Sapin C, Aillaud MF, Gentile S, et al. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost. 2001;85:800-5. Available from http://www.ncbi.nlm.nih.gov/pubmed/11372671.
32. Bertolaccini ML, Roch B, Amengual O, Atsumi T, Khamashta MA, Hughes GR. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br J Rheumatol. 1998;37:1229-32. Available from http://www.ncbi.nlm.nih.gov/pubmed/9851275.
33. Sanmarco M, Boffa M-C. Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome. Lupus. 2009;18:920-3. Available from http://www.ncbi.nlm.nih.gov/pubmed/19671793.
34. Staub HL, Harris EN, Khamashta MA, Savidge G, Chahade WH, Hughes GR. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann Rheum Dis. 1989;48:166-9. Available from http://www.ncbi.nlm.nih.gov/pubmed/2494957.
35. Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, Sanna G, Ateka-Barrutia O, Khamashta MA. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called "seronegative APS"). Ann Rheum Dis. 2012;71:242-4. Available from http://www.ncbi.nlm.nih.gov/pubmed/21953349.
36. Blaschek MA, Boehme M, Jouquan J, Simitzis AM, Fifas S, Le Goff P, et al. Relation of antivimentin antibodies to anticardiolipin antibodies in systemic lupus erythematosus. Ann Rheum Dis. 1988;47:708-16. Available from http://www.ncbi.nlm.nih.gov/pubmed/3052321.
37. Podor TJ, Singh D, Chindemi P, Foulon DM, McKelvie R, Weitz JI, et al. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem. 2002;277:7529-39. Available from http://www.ncbi.nlm.nih.gov/pubmed/11744725.
38. Ortona E, Capozzi A, Colasanti T, Conti F, Alessandri C, Longo A, et al. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood. 2010;116:2960-7. Available from http://www.ncbi.nlm.nih.gov/pubmed/20634382.
39. Alessandri C, Conti F, Pendolino M, Mancini R, Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev. 2011;10:609-16. Available from http://www.ncbi.nlm.nih.gov/pubmed/21545849.
40. Arnold J, Holmes Z, Pickering W, Farmer C, Regan L, Cohen H. Anti-beta 2 glycoprotein 1 and anti-annexin V antibodies in women with recurrent miscarriage. Br. J. Haematol. 2001;113:911-4. Available from http://www.ncbi.nlm.nih.gov/pubmed/11442483.
41. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem. 2001;47:1008-15. Available from http://www.ncbi.nlm.nih.gov/pubmed/11375285.
42. Gris JC, Quéré I, Sanmarco M, Boutiere B, Mercier E, Amiral J, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nîmes obstetricians and haematologists study-NOHA. Thromb Haemost. 2000;84:228-36. Available from http://www.ncbi.nlm.nih.gov/pubmed/10959694.
43. de Laat B, Derksen RHWM, Mackie IJ, Roest M, Schoormans S, Woodhams BJ, et al. Annexin A5 polymorphism (-1C->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis. 2006;65:1468-72. Available from http://www.ncbi.nlm.nih.gov/pubmed/16449315.
44. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem. 1994;269:21191-7. Available from http://www.ncbi.nlm.nih.gov/pubmed/8063740.
45. Kaczan-Bourgois D, Salles JP, Hullin F, Fauvel J, Moisand A, Duga-Neulat I, et al. Increased content of annexin II (p36) and p11 in human placenta brush-border membrane vesicles during syncytiotrophoblast maturation and differentiation. Placenta. 1996;17:669-76. Available from http://www.ncbi.nlm.nih.gov/pubmed/8916217.
46. Cesarman-Maus G, Ríos-Luna NP, Deora AB, Huang B, Villa R, Cravioto M del C, et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood. 2006;107:4375-82. Available from http://www.ncbi.nlm.nih.gov/pubmed/16493010.
47. Baglin T. The measurement and application of thrombin generation. Br J Haematol. 2005;130:653-61. Available from http://www.ncbi.nlm.nih.gov/pubmed/16115120.
48. van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol. 2008;142:889-903. Available from http://www.ncbi.nlm.nih.gov/pubmed/18564356.
49. Chandler WL, Roshal M. Optimization of plasma fluorogenic thrombin-generation assays. Am J Clin Pathol. 2009;132:169-79. Available from http://www.ncbi.nlm.nih.gov/pubmed/19605810.
50. Dienava-Verdoold I, Boon-Spijker MG, de Groot PG, Brinkman HJM, Voorberg J, Mertens K, et al. Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity. J Thromb Haemost. 2011;9:738-47. Available from http://www.ncbi.nlm.nih.gov/pubmed/21255251.
51. Regnault V, Béguin S, Wahl D, de Maistre E, Coenraad Hemker H, Lecompte T. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost. 2003;89:208-12. Available from http://www.ncbi.nlm.nih.gov/pubmed/12574797.
52. Efthymiou M, Lawrie AS, Mackie I, Arachchillage D, Lane PJ, Machin S, et al. Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome. Thromb Res. 2015;135:1191-7. Available from http://www.ncbi.nlm.nih.gov/pubmed/25895847.
53. Zuily S, Ait Aissa K, Membre A, Regnault V, Lecompte T, Wahl D. Thrombin generation in antiphospholipid syndrome. Lupus. 2012;21:758-60. Available from http://www.ncbi.nlm.nih.gov/pubmed/22635224.
54. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827-32. Available from http://www.ncbi.nlm.nih.gov/pubmed/12393574.
55. Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8:237-42. Available from http://www.ncbi.nlm.nih.gov/pubmed/19874470.
56. Sciascia S, Cuadrado MJ, Sanna G, Murru V, Roccatello D, Khamashta MA et al. Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort. Arthritis Care Res. 2014;66:1915-20. Available from http://www.ncbi.nlm.nih.gov/pubmed/24964745.
57. Oku K, Amengual O, Bohgaki T, Horita T, Yasuda S, Atsumi T. An independent validation of the global anti-phospholipid syndrome score in a Japanese cohort of patients with autoimmune diseases. Lupus. 2015;24:774-5. Available from http://www.ncbi.nlm.nih.gov/pubmed/25432782.
58. Sciascia S, Sanna G, Khamashta MA, Cuadrado MJ, Erkan D, Andreoli L, et al. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum Dis. 2015;74:2028-33. Available from http://www.ncbi.nlm.nih.gov/pubmed/24942381.
59. Erkan D, Lockshin MD, APS ACTION members. APS ACTION-antiphospholipid syndrome alliance for clinical trials and international networking. Lupus. 2012;21:695-8. Available from http://www.ncbi.nlm.nih.gov/pubmed/22635205.
60. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res. 2013;65:1869-73. Available from http://www.ncbi.nlm.nih.gov/pubmed/23861221.
61. Chighizola CB, Andreoli L, de Jesus GR, Banzato A, Pons-Estel GJ, Erkan D, et al. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Lupus. 2015;24:980-4. Available from http://www.ncbi.nlm.nih.gov/pubmed/25697769.